Li Ka-shing funds Asia’s first non-invasive kidney tumour trials in Hong Kong
Hong Kong will become the first city in Asia to conduct clinical trials of a non-invasive treatment for kidney tumours, with tycoon Li Ka-shing funding places for 30 patients across three private hospitals. The Li Ka Shing Foundation announced on Wednesday that CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would launch the trials using histotripsy, a…
Hong Kong is set to become the first city in Asia to launch clinical trials of a non-invasive treatment for kidney tumours, thanks to a donation from tycoon Li Ka-shing. The Li Ka Shing Foundation has funded the trials, which will be conducted at CUHK Medical Centre, Gleneagles Hospital Hong Kong, and Hong Kong Sanatorium & Hospital using histotripsy technology.
This innovative treatment, which uses focused sound waves to break apart tumours without surgical incisions, will be tested for its safety and effectiveness in treating kidney cancer. Over 400 patients in Hong Kong have already undergone histotripsy treatment in the past two years, with Gleneagles Hospital Hong Kong and CUHK Medical Centre leading the way in treating pancreatic cancer patients.
The foundation has also provided histotripsy systems to three universities in Hong Kong since 2024 and expanded its "Love Can Help" medical programme to subsidise treatment for liver cancer patients.
Brief written by urgent.news from South China Morning Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.